Renal denervation for resistant hypertension - The Symplicity HTN-1 study

摘要

It must be seen as a regrettable coincidence that just a month after Medtronic (the sponsors of the Symplicity trials) announced that Symplicity HTN-3 had failed to meet its primary efficacy endpoint of a reduction of 10 mm Hg in systolic blood pressure and that all further trials were being suspended, The Lancet should see fit to publish the result of the Symplicity HTN-1 trial and a largely laudatory commentary on renal denervation.